The future is here!
As part of the agreement between Catapult and Diatec Monoclonals for September 2018, Diatec has now moved a significant part of it’s staff to Catapult. Diatec will do their ISO-production in the brand new cleanrooms established at Catapult. By this, their current facilities in Oslo Innovation Centre can be redesigned for full GMP production of biologic drugs for FDA approval.
The timelines for the building and relocation project at Catapult have been extremely tight, and the project has been completed with minimal delay. This achievement had to be celebrated, and this was done with salute, sparkling lemonade and cake at our Friday’s coffee January 11.